On this page

Azelastine Hydrochloride

Prescription ANDA TE AT Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Azelastine Hydrochloride
Generic name
Azelastine Hydrochloride
Dosage form
Solution/ Drops
Route
Intraocular
Marketing category
ANDA · ANDA
Labeler
Sandoz Inc
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
1
NDC product codes
7
Packages
7
Data completeness
83% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Azelastine Hydrochloride .5 mg/mL 860805 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Solution/ Drops
Route of administration
Intraocular
Presentations
14

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Histamine H1 Receptor Antagonists [MoA] MoA All 136 members
Histamine-1 Receptor Antagonist [EPC] EPC All 134 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
210092
Application type
ANDA · Abbreviated New Drug Application
Approval date
February 25, 2020
Sponsor
GLAND
Products on application
1
Submissions recorded
1
Products approved under application 210092.
Product Trade name Form Strength Ingredient Status TE Flags
210092-001 AZELASTINE HYDROCHLORIDE SOLUTION/DROPS AZELASTINE HYDROCHLORIDE Prescription AT

Therapeutic equivalence

Source: Orange Book
TE code
AT
Reference Listed Drug
No
Reference Standard
No

What this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 210092.
Type No. Action Status Date Review
Original application 1 Approved February 25, 2020 Standard

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260908). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20260908 HUMAN PRESCRIPTION DRUG · 20251216 HUMAN PRESCRIPTION DRUG · 20251211 HUMAN PRESCRIPTION DRUG · 20250926

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE: Azelastine hydrochloride ophthalmic solution, 0.05% is indicated for the treatment of itching of the eye associated with allergic conjunctivitis.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION: The recommended dose is one drop instilled into each affected eye twice a day.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS: Azelastine hydrochloride ophthalmic solution, 0.05% is contraindicated in persons with known or suspected hypersensitivity to any of its components.

WARNINGS Azelastine hydrochloride ophthalmic solution, 0.05% is for topical ophthalmic use only and not for injection or oral use.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS In controlled multiple-dose studies where patients were treated for up to 56 days, the most frequently reported adverse reactions were transient eye burning/stinging (approximately 30%), headaches (approximately 15%) and bitter taste (approximately 10%). The occurrence of these events was generally mild. The following events were reported in 1% to 10% of patients: asthma, conjunctivitis, dyspnea, eye pain, fatigue, influenza-like symptoms, pharyngitis, pruritus, rhinitis and temporary blurring. Some of these events were similar to the underlying disease being studied. To report SUSPECTED ADVERSE REACTIONS, contact Fosun Pharma USA Inc. at 1-866-611-3762 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Description

openFDA Drug Labeling

DESCRIPTION Azelastine hydrochloride ophthalmic solution, 0.05% is a sterile ophthalmic solution containing azelastine hydrochloride, a relatively selective H 1 -receptor antagonist for topical administration to the eyes. Azelastine hydrochloride is a white crystalline powder with a molecular weight of 418.37. Azelastine hydrochloride is sparingly soluble in water, methanol and propylene glycol, and slightly soluble in ethanol, octanol and glycerine. Azelastine hydrochloride is a racemic mixture with a melting point of 225°C. The chemical name for azelastine hydrochloride is (±)-1-(2H)-phthalazinone,4-[(4-chlorophenyl) methyl]-2-(hexahydro-1-methyl-1H-azepin-4-yl)-, monohydrochloride and is represented by the following chemical structure: Empirical chemical structure: C 22 H 24 CIN 3 O•HCl Each mL of azelastine hydrochloride ophthalmic solution, 0.05% contains: Active: 0.5 mg azelastine hydrochloride, equivalent to 0.457 mg of azelastine base; Preservative: 0.25 mg benzalkonium chloride solution (50%) USP-NF; Inactives: disodium edetate dihydrate, hypromellose, sorbitol solution, sodium hydroxide and water for injection. It has a pH of approximately 5 to 6.5 and an osmolality of approximately 271 to 312 mOsmol/L. chemical structure

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Azelastine Hydrochloride Ophthalmic Solution USP, 0.05% is supplied as follows: 6 mL (NDC# 60505-0578-4) solution in a translucent 11 mL HDPE container with a LDPE dropper tip, and a white HDPE screw cap. Storage Store UPRIGHT at 20oC to 25oC (68oF to 77oF) [See USP Controlled Room Temperature]. Azelastine Hydrochloride Ophthalmic Solution, USP 0.05% Manufactured by: Manufactured for: Apotex Inc. Apotex Corp. Toronto, Ontario Weston, FL Canada M9L 1T9 33326 September 2025

Adverse event reports

Source: openFDA FAERS
10,538
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: AZELASTINE HYDROCHLORIDE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Recalls

Source: FDA Enforcement
Drug recall enforcement reports associated with this product.
Classification Reported Firm Reason Status
Class II July 2, 2025 Apotex Corp. Lack of Assurance of Sterility Ongoing

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
46708-506-06 46708-506 Alembic Pharmaceuticals Limited 1 BOTTLE in 1 CARTON (46708-506-06) / 6 mL in 1 BOTTLE March 20, 2019
60505-0578-4 60505-0578 Apotex Corp. 1 BOTTLE, PLASTIC in 1 CARTON (60505-0578-4) / 6 mL in 1 BOTTLE, PLASTIC December 1, 2009
72266-141-01 72266-141 Fosun Pharma USA Inc 1 BOTTLE, PLASTIC in 1 CARTON (72266-141-01) / 6 mL in 1 BOTTLE, PLASTIC September 8, 2020
68083-287-01 68083-287 Gland Pharma Limited 1 BOTTLE, PLASTIC in 1 BOX (68083-287-01) / 6 mL in 1 BOTTLE, PLASTIC February 25, 2020
61314-308-02 61314-308 Sandoz Inc 1 BOTTLE, PLASTIC in 1 CARTON (61314-308-02) / 6 mL in 1 BOTTLE, PLASTIC March 21, 2013
70069-091-01 70069-091 Somerset Therapeutics, LLC 1 BOTTLE in 1 CARTON (70069-091-01) / 6 mL in 1 BOTTLE April 8, 2019
47335-938-90 47335-938 Sun Pharmaceutical Industries, Inc. 1 BOTTLE, PLASTIC in 1 BOX (47335-938-90) / 6 mL in 1 BOTTLE, PLASTIC May 31, 2010
46708-506 46708-506 Alembic Pharmaceuticals Limited — March 20, 2019
60505-0578 60505-0578 Apotex Corp. — December 1, 2009
72266-141 72266-141 Fosun Pharma USA Inc — September 8, 2020
68083-287 68083-287 Gland Pharma Limited — February 25, 2020
61314-308 61314-308 Sandoz Inc — March 21, 2013
70069-091 70069-091 Somerset Therapeutics, LLC — April 8, 2019
47335-938 47335-938 Sun Pharmaceutical Industries, Inc. — May 31, 2010

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts
Enforcement FDA Recall records

Generated September 25, 2026 · 13 sections on this page.